Literature DB >> 32078492

Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine.

Nicole Brunet1, David T Moore2,3, Dora Lendvai Wischik3, Kristin M Mattocks4,5, Marc I Rosen2,3.   

Abstract

Background:Having prescribers use clinical video teleconferencing (telemedicine) to prescribe buprenorphine to people with opioid use disorder (OUD) has shown promise but its implementation is challenging. We describe barriers, facilitators and lessons learned while implementing a system to remotely prescribe buprenorphine to Veterans in rural settings.
Methods: We conducted a quality improvement project aimed at increasing the availability of medications for OUD (MOUD) to Veterans. This project focused on tele-prescribing buprenorphine to rural sites via a hub (centralized prescribers) and spoke (rural clinics) model. After soliciting a wide-range of inputs from site visits, qualitative interviews of key stakeholders at rural sites, and review of preliminary cases, a "how-to" toolkit was developed and iteratively refined to guide tele-prescribing of buprenorphine. After internal and external facilitation strategies were employed, Veterans with OUD at three clinics were transitioned to buprenorphine treatment via telemedicine.
Results: Factors impacting adoption of the tele-prescribing intervention were mapped to the Consolidated Framework for Implementation Research (CFIR) constructs. Barriers to adoption included concerns about legality of tele-prescribing a controlled substance, conflicting interests between different stakeholders, and coordination with an existing buprenorphine program requiring more attendance and abstinence from Veterans than the tele-prescribing program required. Factors facilitating adoption included a sense of mission around combating the opioid epidemic, preexisting use of and comfort with tele-prescribing, and rural sites' control over Veterans referred to tele-prescribers. A total of 12 patients from rural areas were successfully transitioned onto buprenorphine, of whom 9 remained on buprenorphine 6 months after initiation of treatment. Conclusions: Implementing tele-prescribing was negotiated with stakeholders at the target clinics and operationalized in a toolkit to guide future efforts. Implementation issues can be addressed by activities that foster collaboration between hubs (centralized prescribers) and spokes (rural clinics) and by a toolkit that operationalizes tele-prescribing procedures.

Entities:  

Keywords:  Medication treatment for OUD (MOUD); buprenorphine; opioid use disorder; telemedicine

Mesh:

Substances:

Year:  2020        PMID: 32078492     DOI: 10.1080/08897077.2020.1728466

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.984


  18 in total

1.  Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.

Authors:  Jessica J Wyse; Kathleen A McGinnis; E Jennifer Edelman; Adam J Gordon; Ajay Manhapra; David A Fiellin; Brent A Moore; P Todd Korthuis; Amy J Kennedy; Benjamin J Oldfield; Julie R Gaither; Kirsha S Gordon; Melissa Skanderson; Declan T Barry; Kendall Bryant; Stephen Crystal; Amy C Justice; Kevin L Kraemer
Journal:  AIDS Behav       Date:  2021-09-08

Review 2.  Expanding access to medications for opioid use disorder through locally-initiated implementation.

Authors:  Jessica J Wyse; Katherine Mackey; Travis I Lovejoy; Devan Kansagara; Anais Tuepker; Adam J Gordon; P Todd Korthuis; Anders Herreid-O'Neill; Beth Williams; Benjamin J Morasco
Journal:  Addict Sci Clin Pract       Date:  2022-06-20

3.  Aligning quality improvement efforts and policy goals in a national integrated health system.

Authors:  Melissa Z Braganza; Elsa Pearson; Cecille Joan Avila; Dave Zlowe; John Øvretveit; Amy M Kilbourne
Journal:  Health Serv Res       Date:  2022-03-04       Impact factor: 3.734

Review 4.  Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.

Authors:  Katherine Mackey; Stephanie Veazie; Johanna Anderson; Donald Bourne; Kim Peterson
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

5.  Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.

Authors:  Allison M Gustavson; Adam J Gordon; Marie E Kenny; Haley McHenry; Julie Gronek; Princess E Ackland; Hildi J Hagedorn
Journal:  Subst Abus       Date:  2020-09-16       Impact factor: 3.716

6.  Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study.

Authors:  Erica Morse; Ingrid A Binswanger; Emmeline Taylor; Caroline Gray; Matthew Stimmel; Christine Timko; Alex H S Harris; David Smelson; Andrea K Finlay
Journal:  J Subst Abuse Treat       Date:  2021-03-04

7.  A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.

Authors:  Emmeline N Taylor; Christine Timko; Ingrid A Binswanger; Alex H S Harris; Matthew Stimmel; David Smelson; Andrea K Finlay
Journal:  Subst Abus       Date:  2021-09-29       Impact factor: 3.984

8.  Well-Being of Health Care Professionals Treating Opioid Use Disorder During the COVID-19 Pandemic: Results From a National Survey.

Authors:  Derek Blevins; Brandy F Henry; Minhee Sung; E Jennifer Edelman; Anne C Black; Michael Dawes; Todd Molfenter; Holly Hagle; Karen Drexler; Kathryn Cates-Wessel; Frances R Levin
Journal:  Psychiatr Serv       Date:  2021-08-09       Impact factor: 3.084

9.  Telehealth Capability Among Substance Use Disorder Treatment Facilities in Counties With High Versus Low COVID-19 Social Distancing.

Authors:  Jonathan Cantor; Bradley D Stein; Brendan Saloner
Journal:  J Addict Med       Date:  2020-12       Impact factor: 4.647

10.  Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.

Authors:  Lewei A Lin; John C Fortney; Amy S B Bohnert; Lara N Coughlin; Lan Zhang; John D Piette
Journal:  J Subst Abuse Treat       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.